Paluku K M, Breman J G, Moore M, Ngimbi N P, Sexton J D, Roy J, Steketee R W, Weinman J M, ma-Disu M
Childhood Communicable Diseases Program, Ministry of Health, Kinshasa, Zaire.
Trans R Soc Trop Med Hyg. 1988;82(3):353-7. doi: 10.1016/0035-9203(88)90113-7.
In vivo sensitivity of Plasmodium falciparum to chloroquine was evaluated in 4 of 9 regions of Zaire in 1985 to develop a national strategy for treatment of malaria. Children less than 5 years of age were treated with either a single dose of chloroquine base, 10 mg/kg, or a dose of 25 mg/kg given over 3 d. A modified 7-day World Health Organization in vivo test was used with follow-up 2, 3 and 7 d after the start of treatment. 339 children were studied. In Bwamanda 92% of children were aparasitaemic 7 days after chloroquine, 10 mg/kg, but in Kinshasa only 44% were free of parasites after 25 mg/kg chloroquine. The mean drop in parasite density among those who did not clear parasites by day 7 was greater than 98% of the initial value. Although the parasite density decreased markedly, the failure of most subjects to become aparasitaemic indicated a marked decrease in parasite sensitivity since 1983. Only one child of 51 who were initially febrile remained febrile, although 14 (28%) of these had resistant parasites. The decrease in parasitaemia and temperature, even among children with resistant strains, led the Ministry of Health to recommend 25 mg/kg chloroquine as first line treatment for fever/malaria in their national malaria control plan. The plan includes drug sensitivity surveillance and a referral system for patients who do not respond to chloroquine treatment.
1985年,在扎伊尔9个地区中的4个地区评估了恶性疟原虫对氯喹的体内敏感性,以制定全国疟疾治疗策略。对5岁以下儿童给予单剂量的氯喹碱,10mg/kg,或在3天内给予25mg/kg的剂量。采用改良的7天世界卫生组织体内试验,并在治疗开始后2、3和7天进行随访。共研究了339名儿童。在布瓦曼达,给予10mg/kg氯喹后,92%的儿童在7天后无寄生虫血症,但在金沙萨,给予25mg/kg氯喹后,只有44%的儿童无寄生虫。到第7天未清除寄生虫的儿童,其寄生虫密度平均下降幅度大于初始值的98%。尽管寄生虫密度显著下降,但大多数受试者未能清除寄生虫血症,这表明自1983年以来寄生虫敏感性显著降低。最初发热的51名儿童中只有1名仍发热,尽管其中14名(28%)有耐药寄生虫。即使在有耐药菌株的儿童中,寄生虫血症和体温的下降也促使卫生部在其国家疟疾控制计划中推荐25mg/kg氯喹作为发热/疟疾的一线治疗药物。该计划包括药物敏感性监测和针对氯喹治疗无反应患者的转诊系统。